The broad long term goal of the PI's laboratory is to help define the mechanisms underlying the progression of various heart diseases to congestive heart failure (CHF). In the present proposal animal models mimic human desmin-related cardiomyopathy (DRC) and hypertensive heart disease will be respectively investigated. Although DRC is not a common heart disease but understanding its pathogenesis will shed lights on many common forms of heart disease, especially those with increased production of abnormal proteins in cardiomyocytes. DRC is the cardiac component of desmin-related myopathy (DRM) which is often caused by genetic mutations. DRM or DRC is characterized by aberrant protein aggregation in muscle cells and this aggregation appears to play a central role in DRC pathogenesis. Notably, abnormal protein aggregation in the form of amyloid oligomers was also observed in human CHF resulting from common forms of heart disease. Intracellular protein aggregation and proteolytic disturbance are recently observed also in pressure overloaded mouse hearts. Hence, pathogenic insights gained from studying DRC may provide critical information for understanding molecular pathogenesis of CHF resulting from common cardiovascular disease. The ubiquitin- proteasome system (UPS) is responsible for the degradation of most cellular proteins and thereby plays indispensible roles in intracellular protein quality control and the regulation of virtually all cellular functions. In the previous project period, we have successfully unveiled severe proteasome (psm) impairment by abnormal protein aggregation in DRC mouse hearts. Notably, psm dysfunction is also observed in animal models of many other cardiac disorders, including pressure overload cardiomyopathy. It has also been implicated in human CHF of most causes. However, the pathophysiological significance of psm dysfunction in the heart is virtually unknown and will be extremely important to be defined. Accordingly, we propose to test an overall hypothesis that the inadequacy in psm-mediated proteolysis plays an essential role in DRC and in pressure overload cardiomyopathy, by pursuing the following 4 Specific Aims: (1) To determine the sufficiency of perinatal or adult onset cardiomyocyte-restricted psm inhibition (CR-PSMI) to induce cardiomyopathy and its reversibility in mice;(2) To investigate the impact of moderate and severe CR-PSMI on the removal of bona fide normal and abnormal proteins in the heart and investigate the functional relationship between psm- mediated proteolysis and autophagy in cardiomyocytes in mice;(3) To determine the necessity of psm functional insufficiency in the pathogenesis of DRC in mice;and (4) To determine the role of psm dysfunction in pressure overload cardiac remodeling and failure in mice.

Public Health Relevance

Congestive heart failure is the final common pathway of virtually all heart disease and is the most expensive single diagnosis in US health care. It is a highly lethal and disabling syndrome. Despite recent advances in its clinical management, it remains the leading cause of death in the US. This research project will help deepen our understanding on the molecular mechanisms underlying the progression of various heart diseases to congestive heart failure, which will ultimately facilitate the search for new measures to prevent or more effectively treat this common and yet life-threatening disorder.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL072166-10
Application #
8449618
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Wang, Lan-Hsiang
Project Start
2002-12-01
Project End
2014-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$338,115
Indirect Cost
$102,495
Name
University of South Dakota
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
929930808
City
Vermillion
State
SD
Country
United States
Zip Code
57069
Cui, Taixing; Lai, Yimu; Janicki, Jospeh S et al. (2016) Nuclear factor erythroid-2 related factor 2 (Nrf2)-mediated protein quality control in cardiomyocytes. Front Biosci (Landmark Ed) 21:192-202
Zhao, C; Chen, X; Zang, D et al. (2016) A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene 35:5916-5927
Zhang, Lei; Hapon, Maria B; Goyeneche, Alicia A et al. (2016) Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. Mol Oncol 10:1099-117
Huang, Hongbiao; Liao, Yuning; Liu, Ningning et al. (2016) Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. Oncotarget 7:2796-808
Hou, Ning; Ye, Bo; Li, Xiang et al. (2016) Transcription Factor 7-like 2 Mediates Canonical Wnt/β-Catenin Signaling and c-Myc Upregulation in Heart Failure. Circ Heart Fail 9:
Li, Jie; Ma, Wenxia; Yue, Guihua et al. (2016) Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy. J Mol Cell Cardiol 102:53-60
Liu, Jinbao; Su, Huabo; Wang, Xuejun (2016) The COP9 signalosome coerces autophagy and the ubiquitin-proteasome system to police the heart. Autophagy 12:601-2
Qin, Qingyun; Qu, Chen; Niu, Ting et al. (2016) Nrf2-Mediated Cardiac Maladaptive Remodeling and Dysfunction in a Setting of Autophagy Insufficiency. Hypertension 67:107-17
(2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222
Zhao, Chong; Chen, Xin; Zang, Dan et al. (2016) Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. Biochem Pharmacol 116:22-38

Showing the most recent 10 out of 91 publications